{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:46:24Z","timestamp":1777441584566,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"am","delay-in-days":330,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ahj.2020.04.013","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T02:33:53Z","timestamp":1588214033000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial"],"prefix":"10.1016","volume":"225","author":[{"given":"Marc","family":"Laine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Lemesle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Burtey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Cayla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Range","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Quaino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Canault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Pankert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Puymirat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Bonello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2020.04.013_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2020.04.013_bb0010","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1681\/ASN.2005121273","article-title":"International comparison of the relationship of chronic kidney disease prevalence and ESRD risk","volume":"17","author":"Hallan","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2020.04.013_bb0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.7326\/M16-0273","article-title":"Trends in prevalence of chronic kidney disease in the United States","volume":"165","author":"Murphy","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2020.04.013_bb0020","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/ndt\/gfr323","article-title":"Epidemiology and prognostic significance of chronic kidney disease in the elderly\u2014the Three-City prospective cohort study","volume":"26","author":"Stengel","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ahj.2020.04.013_bb0025","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2020.04.013_bb0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ahj.2013.03.016","article-title":"Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States","volume":"166","author":"Foster","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2020.04.013_bb0035","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2020.04.013_bb0040","doi-asserted-by":"crossref","first-page":"I80","DOI":"10.1161\/01.HYP.13.5_Suppl.I80","article-title":"Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group","volume":"13","author":"Shulman","year":"1989","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2020.04.013_bb0045","first-page":"352","article-title":"Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention","volume":"80","author":"Parikh","year":"2012","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.04.013_bb0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2369-15-66","article-title":"Impact of impaired glomerular filtration rate and revascularization strategy on one-year cardiovascular events in acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry","volume":"15","author":"Lin","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ahj.2020.04.013_bb0055","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/eurheartj\/ehp014","article-title":"Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction","volume":"30","author":"Wong","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.013_bb0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"Fox","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.013_bb0065","volume":"2017","author":"Ibanez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.013_bb0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.013_bb0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"The Lancet"},{"key":"10.1016\/j.ahj.2020.04.013_bb0080","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.04.013_bb0085","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jacc.2009.10.043","article-title":"Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy","volume":"55","author":"Angiolillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.04.013_bb0090","first-page":"295","article-title":"Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation","volume":"59","author":"Barragan","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.04.013_bb0095","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/11599830-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies","volume":"51","author":"Husted","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ahj.2020.04.013_bb0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ahj.2010.11.025","article-title":"The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET\/OFFSET and RESPOND studies","volume":"162","author":"Bliden","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2020.04.013_bb0105","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.013_bb0110","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.thromres.2013.04.030","article-title":"Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention","volume":"132","author":"Laine","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2020.04.013_bb0115","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1177\/0091270011415526","article-title":"Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment","volume":"52","author":"Butler","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2020.04.013_bb0120","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1053\/j.ajkd.2014.11.023","article-title":"Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study","volume":"65","author":"Jeong","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2020.04.013_bb0125","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahj.2020.04.013_bb0130","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jcmg.2013.12.016","article-title":"Atherosclerotic versus nonatherosclerotic evaluation: the yin and yang of cardiovascular imaging in advanced chronic kidney disease","volume":"7","author":"Herzog","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2020.04.013_bb0135","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/phar.2018","article-title":"Contemporary time trends in use of antiplatelet agents among patients with acute coronary syndrome and comorbid diabetes mellitus or chronic kidney disease","volume":"37","author":"Desai","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ahj.2020.04.013_bb0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jth.13904","article-title":"Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study","volume":"16","author":"Ocak","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2020.04.013_bb0145","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/clc.22253","article-title":"Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non\u2013ST-elevation acute coronary syndrome","volume":"37","author":"Rhee","year":"2014","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ahj.2020.04.013_bb0150","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.013_bb0155","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.04.013_bb0160","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.013_bb0165","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.jcin.2016.06.051","article-title":"Chronic kidney disease in the second-generation drug-eluting stent era: pooled analysis of the Korean Multicenter Drug-Eluting Stent Registry","volume":"9","author":"Lee","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.04.013_bb0170","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.04.013_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2019.05.002","article-title":"Statin therapy among chronic kidney disease patients presenting with acute coronary syndrome","volume":"286","author":"Natanzon","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2020.04.013_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060810","article-title":"Prognostic value of incomplete revascularization after percutaneous coronary intervention following acute coronary syndrome: focus on CKD patients","volume":"8","author":"Cardi","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ahj.2020.04.013_bb0185","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MCA.0b013e3282f08e99","article-title":"Screening for significant coronary artery disease in high-risk renal transplant candidates","volume":"18","author":"Gowdak","year":"2007","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.ahj.2020.04.013_bb0190","article-title":"One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry","author":"Scholz","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ahj.2020.04.013_bb0195","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/joic.12469","volume":"31","author":"Sato","year":"2018","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.ahj.2020.04.013_bb0200","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/heartjnl-2017-312436","article-title":"Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function","volume":"104","author":"Edfors","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2020.04.013_bb0205","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/CIRCULATIONAHA.108.838169","volume":"120","author":"Szummer","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.013_bb0210","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.013_bb0215","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jcin.2011.06.012","volume":"4","author":"Saltzman","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.04.013_bb0220","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/ndt\/gft027","article-title":"Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options","volume":"28","author":"Morel","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ahj.2020.04.013_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.ahj.2020.04.013_bb0230","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1161\/CIRCULATIONAHA.118.032078","article-title":"P2Y12-ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes","volume":"138","author":"Bonello","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.013_bb0235","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.013_bb0240","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/ndt\/4.11.971","article-title":"Hyperparathyroidism does not influence the abnormal primary haemostasis in patients with chronic renal failure","volume":"4","author":"Vigan\u00f2","year":"1989","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ahj.2020.04.013_bb0245","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/ndt\/gfg185","article-title":"Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients","volume":"18","author":"Moal","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ahj.2020.04.013_bb0250","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0272-6386(12)80429-X","article-title":"Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia","volume":"22","author":"Benigni","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2020.04.013_bb0255","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahj.2020.04.013_bb0260","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1055\/s-0038-1669426","article-title":"Meta-analysis of potent P2Y12-ADP receptor antagonist therapy compared to clopidogrel therapy in acute coronary syndrome patients with chronic kidney disease","volume":"118","author":"Bonello","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2020.04.013_bb0265","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jcin.2017.02.047","article-title":"Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the PROMETHEUS study","volume":"10","author":"Baber","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.04.013_bb0270","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2008.04.040","article-title":"Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome","volume":"102","author":"Bonello","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2020.04.013_bb0275","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non\u2013ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:57:32Z","timestamp":1762077452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320301216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":55,"alternative-id":["S0002870320301216"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.04.013","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}